All Stories

  1. Serum KL-6 as a Biomarker of Progression at Any Time in Fibrotic Interstitial Lung Disease
  2. MUC5B rs35705950 minor allele associates with older age and better survival in idiopathic pulmonary fibrosis
  3. European Respiratory Society Statement on Familial Pulmonary Fibrosis
  4. Lung cancer in patients with idiopathic pulmonary fibrosis: A retrospective multicentre study in Europe
  5. Integrating Clinical Probability into the Diagnostic Approach to Idiopathic Pulmonary Fibrosis: An International Working Group Perspective
  6. COVID-19 in patients with Pulmonary Alveolar Proteinosis A European multicenter study
  7. Genetic testing in interstitial lung disease: An international survey
  8. Meta-Analysis of Effect of Nintedanib on Reducing FVC Decline Across Interstitial Lung Diseases
  9. Targeted therapy for pulmonary alveolar proteinosis: the time is now
  10. Predictors of mortality in subjects with progressive fibrosing interstitial lung diseases
  11. Communicating with patients with idiopathic pulmonary fibrosis: can we do it better?
  12. Idiopathic pulmonary fibrosis: Physician and patient perspectives on the pathway to care from symptom recognition to diagnosis and disease burden
  13. Modified GAP index by including serum KL-6 to assess risk of disease progression in patients with interstitial lung diseases (ILD): preliminary results from the VAMOS study
  14. Potential clinical utility of MUC5B und TOLLIP single nucleotide polymorphisms (SNPs) in the management of patients with IPF
  15. Chest radiography or computed tomography for COVID-19 pneumonia? Comparative study in a simulated triage setting
  16. Potential clinical utility of MUC5B und TOLLIP single nucleotide polymorphisms (SNPs) in the management of patients with IPF
  17. S2K Guideline for Diagnosis of Idiopathic Pulmonary Fibrosis
  18. Potential Clinical Utility of MUC5B und TOLLIP Single Nucleotide Polymorphisms (SNPs) in the Management of Patients with IPF
  19. Inhaled Molgramostim Therapy in Autoimmune Pulmonary Alveolar Proteinosis
  20. Mechanisms of progressive fibrosis in connective tissue disease (CTD)-associated interstitial lung diseases (ILDs)
  21. Ganzlungenlavage bei pulmonaler Alveolarproteinose – Schritt für Schritt
  22. Clinical burden of idiopathic pulmonary fibrosis (IPF): physician and patient perception
  23. Adiponectin and leptin levels in idiopathic pulmonary fibrosis: A new method for BAL and serum assessment
  24. When the Game Changes
  25. Hypersensitivity pneumonitis
  26. The perpetual enigma of bronchoalveolar lavage fluid lymphocytosis in chronic hypersensitivity pneumonitis: is it of diagnostic value?
  27. Looking into the future of sarcoidosis: what is next for treatment?
  28. Shedding light on developmental drugs for idiopathic pulmonary fibrosis
  29. Serum KL‐6 concentrations as a novel biomarker of severe COVID‐19
  30. A Systematically Derived Exposure Assessment Instrument for Chronic Hypersensitivity Pneumonitis
  31. Krebs von den Lungen-6 as a biomarker for disease severity assessment in interstitial lung disease: a comprehensive review
  32. Efficacy, safety, and tolerability of combined pirfenidone and N-acetylcysteine therapy: a systematic review and meta-analysis
  33. Drug-induced sarcoidosis-like reaction in adjuvant immunotherapy: Increased rate and mimicker of metastasis
  34. S2K-Leitlinie zur Diagnostik der idiopathischen Lungenfibrose
  35. Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial
  36. Genotype in MUC5B-Promoter Polymorphism and Chronic Lung Allograft Dysfunction (CLAD) in a German Cohort: Preliminary Results
  37. S2K-Leitlinie zur Diagnostik der idiopathischen Lungenfibrose
  38. Therapie von Komplikationen und nichtpharmakologisches Management der idiopathischen pulmonalen Fibrose
  39. Azathioprine for Connective Tissue Disease-Associated Interstitial Lung Disease
  40. Baseline High-Resolution CT Findings Predict Acute Exacerbation of Idiopathic Pulmonary Fibrosis: German and Japanese Cohort Study
  41. Therapie der systemischen Sklerose-assoziierten interstitiellen Lungenerkrankung
  42. Quantitative Lipidomics in Pulmonary Alveolar Proteinosis
  43. Shaping the future of an ultra-rare disease
  44. Editorial introductions
  45. Resequencing Study Confirms That Host Defense and Cell Senescence Gene Variants Contribute to the Risk of Idiopathic Pulmonary Fibrosis
  46. Cardiovascular safety of nintedanib in subgroups by cardiovascular risk at baseline in the TOMORROW and INPULSIS trials
  47. Correction to: The Burden of Sarcoidosis Symptoms from a Patient Perspective
  48. Pulmonary alveolar proteinosis
  49. The Burden of Sarcoidosis Symptoms from a Patient Perspective
  50. Changes in serum KL-6 levels are associated with the development of chronic lung allograft dysfunction in lung transplant recipients
  51. Erratum zu: Differenzialdiagnose interstitieller Lungenerkrankungen – „Interstitial pneumonia with autoimmune features“ (IPAF)
  52. Utility of Anti-DSF70 Antibodies to Predict Connective Tissue Disease in Patients Originally Presenting with Idiopathic Interstitial Pneumonia
  53. Nailfold Capillaroscopy Characteristics of Antisynthetase Syndrome and Possible Clinical Associations: Results of a Multicenter International Study
  54. Differenzialdiagnose interstitieller Lungenerkrankungen
  55. Die „Rheumalunge“ in der Computertomographie: radiologische Manifestationen der rheumatoiden Arthritis
  56. The Management of Patients With Idiopathic Pulmonary Fibrosis
  57. Identification of Diagnostic Criteria for Chronic Hypersensitivity Pneumonitis. An International Modified Delphi Survey
  58. Patientenfragebogen zur Erfassung der Ursachen interstitieller und seltener Lungenerkrankungen – klinische Sektion der DGP
  59. Patients with IPF and lung cancer: diagnosis and management
  60. German Guideline for Idiopathic Pulmonary Fibrosis – Update on Pharmacological Therapies 2017
  61. Phenotypes of organ involvement in sarcoidosis
  62. Gastroesophageal Reflux Disease in Idiopathic Pulmonary Fibrosis: Uncertainties and Controversies
  63. Metformin Does Not Affect Clinically Relevant Outcomes in Patients with Idiopathic Pulmonary Fibrosis
  64. Statin Therapy and Outcomes in Trials of Nintedanib in Idiopathic Pulmonary Fibrosis
  65. Serum YKL-40 in workers at an indium-tin oxide production facility - Reply
  66. Idiopathic pleuroparenchymal fibroelastosis (PPFE) – A case study of a rare entity
  67. Therapeutic targets in idiopathic pulmonary fibrosis
  68. Unmet needs in the treatment of idiopathic pulmonary fibrosis―insights from patient chart review in five European countries
  69. Differential diagnosis of granulomatous lung disease: clues and pitfalls
  70. Serum YKL-40 is a reliable biomarker for pulmonary alveolar proteinosis
  71. S2k-Leitlinie Idiopathische Lungenfibrose – Update zur medikamentösen Therapie 2017
  72. FAM13A polymorphism as a prognostic factor in patients with idiopathic pulmonary fibrosis
  73. Antacid Therapy and Disease Progression in Patients with Idiopathic Pulmonary Fibrosis Who Received Pirfenidone
  74. Coagulation factor XII regulates inflammatory responses in human lungs
  75. Serum YKL-40 as predictor of outcome in hypersensitivity pneumonitis
  76. Daily Home Spirometry: A New Milestone in the Field of Pulmonary Fibrosis
  77. Effect of statins on disease-related outcomes in patients with idiopathic pulmonary fibrosis
  78. Deutschsprachige Validierung des „Kingʼs Brief Interstitial Lung Disease (K-BILD)“ Lebensqualitätsfragebogens für interstitielle Lungenerkrankungen
  79. New insights on patient-reported outcome measures in idiopathic pulmonary fibrosis
  80. Whole lung lavage therapy for pulmonary alveolar proteinosis: a global survey of current practices and procedures
  81. Epidemiologie und klinisches Erscheinungsbild der Sarkoidose
  82. A Global Survey on Whole Lung Lavage in Pulmonary Alveolar Proteinosis
  83. European idiopathic pulmonary fibrosis Patient Charter: a missed opportunity
  84. MUC1 gene polymorphisms are associated with serum KL-6 levels and pulmonary dysfunction in pulmonary alveolar proteinosis
  85. How to handle IPF – the new Portuguese consensus document
  86. An Important Step Forward, but Still a Way to Go
  87. Insights from the German Compassionate Use Program of Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis
  88. Idiopathic pulmonary fibrosis: current treatment options and critical appraisal of nintedanib
  89. Pulmonary alveolar proteinosis in a cat
  90. European IPF Patient Charter: unmet needs and a call to action for healthcare policymakers
  91. Pulmonale Alveolarproteinose
  92. Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis
  93. New guideline on treatment of idiopathic pulmonary fibrosis
  94. GATA2 deficiency in children and adults with severe pulmonary alveolar proteinosis and hematologic disorders
  95. Positionspapier zur Bedeutung der forcierten Vitalkapazität für Patienten mit idiopathischer Lungenfibrose (IPF)
  96. Facts and promises on lung biomarkers in interstitial lung diseases
  97. Diagnosis of Sarcoidosis
  98. Update on therapeutic management of idiopathic pulmonary fibrosis
  99. Extracellular 20S proteasome in BAL and serum of patients with alveolar proteinosis
  100. MUC5Bpromoter polymorphism in Japanese patients with idiopathic pulmonary fibrosis
  101. Pharmacological Treatment of Idiopathic Pulmonary Fibrosis: Current Approaches, Unsolved Issues, and Future Perspectives
  102. Alveolar and intraparenchymal proteasome in sarcoidosis
  103. Differential diagnosis of usual interstitial pneumonia: when is it truly idiopathic?
  104. Baseline KL-6 predicts increased risk for acute exacerbation of idiopathic pulmonary fibrosis
  105. Biomarkers in Connective Tissue Disease-Associated Interstitial Lung Disease
  106. Interstitial lung disease
  107. Differences in serum SP-D levels between German and Japanese subjects are associated with SFTPDgene polymorphisms
  108. CCL18 in serum, BAL fluid and alveolar macrophage culture supernatant in interstitial lung diseases
  109. The Ambitious Goal of Validating Prognostic Biomarkers for Systemic Sclerosis-related Interstitial Lung Disease
  110. Macrolides inhibit cytokine production by alveolar macrophages in bronchiolitis obliterans organizing pneumonia
  111. Klinische Erfahrungen mit Pirfenidon in der Therapie der idiopathischen Lungenfibrose
  112. Sarkoidose
  113. Klinische Erfahrungen mit Pirfenidon in der Therapie der idiopathischen Lungenfibrose
  114. Serum KL-6 is a predictor of outcome in pulmonary alveolar proteinosis
  115. Different MUC1 gene polymorphisms in German and Japanese ethnicities affect serum KL-6 levels
  116. Diagnostic approach to interstitial pneumonias in a single centre: report on 88 cases
  117. Hypersensitivity Pneumonitis
  118. Wash-out kinetics and efficacy of a modified lavage technique for alveolar proteinosis
  119. Chronic Hypersensitivity Pneumonitis
  120. KL-6, a Human MUC1 Mucin, as a prognostic marker for diffuse alveolar hemorrhage syndrome
  121. Self-reported asthma and respiratory symptoms among Italian amateur athletes
  122. Whole-Lung Lavage: A Successful Treatment for Restoring Acinar Ventilation Distribution in Primary Acquired Pulmonary Alveolar Proteinosis
  123. Comparison of serum KL-6 versus bronchoalveolar lavage neutrophilia for the diagnosis of bronchiolitis obliterans in lung transplantation
  124. Pulmonary alveolar proteinosis: New insights from a single-center cohort of 70 patients
  125. Therapie der Lungenfibrose
  126. Diagnostic Modalities in Sarcoidosis: BAL, EBUS, and PET
  127. A female soccer player with recurrent haemoptysis and iron deficiency anaemia: idiopathic pulmonary haemosiderosis (IPH)--case report and literature review
  128. Angiogenic and Angiostatic Chemokines in Idiopathic Pulmonary Fibrosis and Granulomatous Lung Disease
  129. To BAL or Not to BAL: Is This a Problem in Diagnosing IPF?
  130. Die bronchoalveoläre Lavage aus klinischer Sicht
  131. Significance of Bronchoalveolar Lavage for the Diagnosis of Idiopathic Pulmonary Fibrosis
  132. Acid reflux into the oesophagus does not influence exercise-induced airway narrowing in bronchial asthma
  133. Bronchoalveolar Lavage in Other Interstitial Lung Diseases
  134. Omeprazole reduces the response to capsaicin but not to methacholine in asthmatic patients with proximal reflux
  135. Biomarkers